A Phase II Study of JNJ-212082 (Abiraterone Acetate) in Metastatic Castration-Resistant Prostate Cancer Patients Who Have Received Docetaxel-based Chemotherapy
收藏DataCite Commons2025-09-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00005175/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to investigate the safety and efficacy of abiraterone in participants with metastatic castration-resistant prostate cancer (mCRPC) who have received docetaxel-based chemotherapy (treatment of disease, usually cancer, by chemical agents).
提供机构：
Vivli
创建时间：
2020-02-04
